The Rights Issue is being carried out to strengthen the Company’s financial position, provide additional scope for the ongoing commercialization of Pepaxti in Europe, and advance the Company’s preclinical project for the indication glioblastoma to the clinical development phase.
March 9, 2026 – Oncopeptides today announces that it has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies (Läkemedelsverket, MPA and Direktoratet for medisinske produkter, DMP) regarding the design of its planned “Window-of-Opportunity” (WoO) study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma. The study will be conducted in Norway, where DMP has granted fast-track designation.
March 9, 2026 – Sofia Heigis, CEO of Oncopeptides, recently visited the Biostock studio to present the company, its’ ambitions for Pepaxti in Europe and rest of the world and also outline the company´s strategic pivot into a multi-indication global biotech, spearheaded by its glioblastoma project.
Released February 19, 2026
CEO Sofia Heigis
David Augustsson
Director of IR and Communications
ir@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2026 will be published May 13, 2026
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreMarch 9, 2026
Read moreDecember 31, 2025
Oncopeptides recently announced new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations.
Read moreNovember 12, 2025
The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals.
Read more
February 20, 2026
Redeye analyst Richard Remanius recently interviewed CEO Sofia Heigis about Q4 and the upcoming new share issue of approximately SEK 200 million.
Read morePress release - March 9, 2026
2026-04-13 - 2026-05-12
Other
2026-05-13
Report
2026-05-21
Meeting
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
